Prostate Cancer Survivorship
ECHO Session Materials
Recorded June 24, 2021
Guest Speaker: David Duchene, MD
Recorded June 24, 2021
Guest Speaker: William Parker, MD
References and Resources
References:
DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252-271.
Noonan EM, Farrell TW. Am Fam Physician. 2016;93(9):764-770
Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363(19):1822–32.
Sandhu JS. Treatment options for post-prostatectomy incontinence. UrolPract. 2014;1(4):194-197.
Kumar A, Litt ER, Ballert KN et al: Artificial urinary sphincter versus male sling for postprostatectomy incontinenced what do patients choose? J Urol 2009; 181: 1231.
Litwiller SE, Kim KB, Fone PD et al: Postprostatectomy incontinence and the artificial urinary sphincter: a long-term study of patient satisfaction and criteria for success. J Urol 1996; 156: 1975.
Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013; 368(5):436-445.
Noonan EM, Farrell TW. Am Fam Physician. 2016;93(9):764-770.
Hanchanale V, Eardley I. Rehabilitation of erectile function after radical prostatectomy. Eur Urol Suppl. 2013;12(2):18-24.
Morgans AK, Smith MR, O’Malley AJ, Keating NL. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer. 2013;119(4):863-870.
Challa AA, Calaway AC, Cardiovascular Toxicities of Androgen Deprivation Therapy. Curr Treat. Options in Oncol. 2021;22:47. DOI 10.1007/s11864-021-00846-z
Levine GN, D’Amico AV, et al. Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. Circulation. 2010 February 16; 121(6): 833–840. doi:10.1161/CIRCULATIONAHA.109.192695
Clinical Guidelines:
NCCN Prostate Cancer Guidelines
NCCN Cancer Survivorship Guidelines
American Cancer Society Prostate Cancer Survivorship Care Guidelines